Drugs such as tamoxifen that directly antagonize ER lie in the core of breast cancer treatment; however, approximately 30% of ER-positive breast cancers exhibit de novo resistance, and 40% acquire resistance to these therapies [82]. Here, ESR1 is linked to breast cancer.